Monitor upcoming data from Study 304 (male confirmatory Phase 3) and Study 306 (female trial) in the second half of 2026, as well as regulatory interactions, which will be critical for confirming VDPHL01's path to approval and commercialization.
Price Chart
Executive Summary
Veradermics announced positive topline results from its Phase 2/3 Study 302 evaluating VDPHL01, an oral extended-release minoxidil, in males with mild-to-moderate pattern hair loss. The trial met all primary and key secondary endpoints with high statistical significance, showing robust hair growth and a favorable safety profile, positioning VDPHL01 as a potential best-in-class treatment.
Key Facts
- VDPHL01 achieved statistically significant improvements in target area hair count (TAHC) at Month 6: +30.3 hairs/cm² (QD) and +33.0 hairs/cm² (BID) vs. +7.3 for placebo (p<0.0001)
- 79.3% (QD) and 86.0% (BID) of patients reported any improvement in patient-reported outcomes (PRO) vs. 35.6% for placebo
- 48.4% (QD) and 62.9% (BID) of patients reported 'improved' or 'much improved' vs. 13.4% for placebo
- No treatment-related serious adverse events (SAEs) or adverse events of special interest (AESIs) of cardiac origin were observed
- VDPHL01 demonstrated a favorable safety profile with overall adverse event rates similar to placebo
Financial Impact
No direct financial figures disclosed, but the successful trial significantly increases the probability of regulatory approval and commercial success for VDPHL01, potentially creating a new $30B market opportunity
Risk Factors
- Future trial results may not replicate these positive outcomes
- Regulatory approval is not guaranteed despite positive data
- Commercial success depends on market adoption and competition
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-027354 |
| Exhibit: exhibit991-8xk.htm | 0001628280-26-027354 |
| Document: mane-20260427.htm | 0001628280-26-027354 |
| Document: 0001628280-26-027354-index-headers.html | 0001628280-26-027354 |
| Document: 0001628280-26-027354-index.html | 0001628280-26-027354 |
| Document: 0001628280-26-027354.txt | 0001628280-26-027354 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $122.28 | awaiting T+5 | — | $137.39 (+12.36%) |
Oct 13, 2026 13d ago | SC 13G | $116.26 $127.11 | ▲ +9.33% | ▲ +10.48% | $137.39 (+18.17%) |
Aug 21, 2026 9w ago | Insider Cluster | $98.46 $98.41 | ▲ +0.05% | ▲ +0.52% | $137.39 (−39.54%) |
Aug 20, 2026 9w ago | 3 | $102.82 $97.93 | ▼ −4.76% | ▼ −5.23% | $137.39 (+33.62%) |
Aug 18, 2026 9w ago | Insider Cluster | $111.23 $102.80 | ▼ −7.58% | ▼ −7.19% | $137.39 (+23.52%) |
Aug 11, 2026 10w ago | 8-K | $110.75 $111.31 | ▲ +0.51% | ▲ +0.91% | $137.39 (+24.05%) |
Aug 7, 2026 11w ago | S-1 | $110.75 $108.22 | ▲ +2.28% | ▲ +2.24% | $137.39 (−24.05%) |
Aug 7, 2026 11w ago | Institutional Cluster | $114.39 $112.71 | ▼ −1.47% | ▼ −1.87% | $137.39 (+20.11%) |
Jul 15, 2026 14w ago | 8-K | $123.70 $109.85 | ▼ −11.20% | ▼ −10.22% | $137.39 (+11.07%) |
May 12, 2026 23w ago | 8-K | $103.90 $100.38 | ▼ −3.39% | ▼ −3.47% | $137.39 (+32.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers